SK Life Science, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- 101
- Market Cap
- -
Cenobamate Expanded Access Program (EAP)
- Conditions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- SK Life Science, Inc.
- Registration Number
- NCT04513860
Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT04505397
- Locations
- πΊπΈ
Spaulding Clinical Research, West Bend, Wisconsin, United States
Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04062981
- Locations
- πΊπΈ
UW Valley Medical Center, Renton, Washington, United States
πΊπΈJohns Hopkins Hospital, Baltimore, Maryland, United States
πΊπΈDartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Cenobamate Open-Label Extension Study for YKP3089C025
- Conditions
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 145
- Registration Number
- NCT03961568
- Locations
- πΊπ¦
Municipal Institution Zaporizhzhia Regional Clinical Hospital of Zaporizhzhia Regional Council, Zaporozhye, Zaporizhzhya, Ukraine
πΊπ¦Communal Institution "Dnipropetrovsk Regional Clinical Hospital n.a. I.I. Mechnikov", Regional Center, Dnipropetrovs'k, Ukraine
πΊπ¦Regional Psyconeurology Hospital #3, Ivano-Frankivs'k, Ukraine
Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03731715
- Locations
- πΊπΈ
Duke Health, Durham, North Carolina, United States
πΊπΈHospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈUW Valley Medical Center, Renton, Washington, United States
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT03678753
- Locations
- πΊπΈ
Ohio Health Research and Innovation Institute, Columbus, Ohio, United States
πΊπΈDuke University Children's Health Center, Durham, North Carolina, United States
πΊπΈUniversity of Toledo, Toledo, Ohio, United States
A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users
- Conditions
- Interventions
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT03509285
- Locations
- πΊπΈ
Vince & Associates Clinical Research, Inc, Overland Park, Kansas, United States
π¨π¦INC Research, Inc., Toronto, Ontario, Canada
Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs as a Means of Predicting Drug-drug Interactions
- Conditions
- Interventions
- First Posted Date
- 2017-07-31
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03234699
- Locations
- πΊπΈ
Vince and Associates Clinical Research, Inc., Overland Park, Kansas, United States
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 1345
- Registration Number
- NCT02535091
- Locations
- πΊπΈ
Blue Sky Neurology, Englewood, Colorado, United States
πΊπΈComprehensive Epilepsy Care Center for Children and Adults PC, Chesterfield, Missouri, United States
πΊπΈNortheast Regional Epilepsy Group, Hackensack, New Jersey, United States
A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT02205099
- Locations
- πΊπΈ
Glendale Adventist Medical Center, Glendale, California, United States